vs
安进（AMGN）与Ardent Health, Inc.（ARDT）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Ardent Health, Inc.的6.1倍（$9.9B vs $1.6B）。安进净利率更高（13.5% vs 2.8%，领先10.7%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Goodlife Health Clubs是一家健身俱乐部连锁品牌，在澳大利亚拥有超过80家门店，是当地颇具规模的健身服务提供商，为消费者提供专业的健身场地、器械及相关健身体验服务。
AMGN vs ARDT — 直观对比
营收规模更大
AMGN
是对方的6.1倍
$1.6B
净利率更高
AMGN
高出10.7%
2.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $1.6B |
| 净利润 | $1.3B | $45.0M |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 5.8% |
| 净利率 | 13.5% | 2.8% |
| 营收同比 | 8.6% | — |
| 净利润同比 | 112.6% | — |
| 每股收益（稀释后） | $2.45 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNARDT
| Q4 25 | $9.9B | $1.6B | ||
| Q3 25 | $9.6B | $1.6B | ||
| Q2 25 | $9.2B | $1.6B | ||
| Q1 25 | $8.1B | $1.5B | ||
| Q4 24 | $9.1B | — | ||
| Q3 24 | $8.5B | $1.4B | ||
| Q2 24 | $8.4B | $1.5B | ||
| Q1 24 | $7.4B | — |
净利润AMGNARDT
| Q4 25 | $1.3B | $45.0M | ||
| Q3 25 | $3.2B | $-23.5M | ||
| Q2 25 | $1.4B | $73.0M | ||
| Q1 25 | $1.7B | $41.4M | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $2.8B | $26.3M | ||
| Q2 24 | $746.0M | $42.8M | ||
| Q1 24 | $-113.0M | — |
毛利率AMGNARDT
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNARDT
| Q4 25 | 27.6% | 5.8% | ||
| Q3 25 | 26.4% | -0.1% | ||
| Q2 25 | 28.9% | 7.4% | ||
| Q1 25 | 14.5% | 5.0% | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 24.1% | 3.9% | ||
| Q2 24 | 22.8% | 5.6% | ||
| Q1 24 | 13.3% | — |
净利率AMGNARDT
| Q4 25 | 13.5% | 2.8% | ||
| Q3 25 | 33.7% | -1.5% | ||
| Q2 25 | 15.6% | 4.4% | ||
| Q1 25 | 21.2% | 2.8% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 33.3% | 1.8% | ||
| Q2 24 | 8.9% | 2.9% | ||
| Q1 24 | -1.5% | — |
每股收益（稀释后）AMGNARDT
| Q4 25 | $2.45 | $0.32 | ||
| Q3 25 | $5.93 | $-0.17 | ||
| Q2 25 | $2.65 | $0.52 | ||
| Q1 25 | $3.20 | $0.29 | ||
| Q4 24 | $1.17 | — | ||
| Q3 24 | $5.22 | $0.19 | ||
| Q2 24 | $1.38 | $0.34 | ||
| Q1 24 | $-0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $709.6M |
| 总债务越低越好 | $54.6B | $1.1B |
| 股东权益账面价值 | $8.7B | $1.3B |
| 总资产 | $90.6B | $5.3B |
| 负债/权益比越低杠杆越低 | 6.31× | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资AMGNARDT
| Q4 25 | $9.1B | $709.6M | ||
| Q3 25 | $9.4B | $609.4M | ||
| Q2 25 | $8.0B | $540.6M | ||
| Q1 25 | $8.8B | $495.0M | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $9.0B | $563.1M | ||
| Q2 24 | $9.3B | $334.5M | ||
| Q1 24 | $9.7B | — |
总债务AMGNARDT
| Q4 25 | $54.6B | $1.1B | ||
| Q3 25 | $54.6B | $1.1B | ||
| Q2 25 | $56.2B | $1.1B | ||
| Q1 25 | $57.4B | $1.1B | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | $1.1B | ||
| Q2 24 | $62.6B | $1.1B | ||
| Q1 24 | $64.0B | — |
股东权益AMGNARDT
| Q4 25 | $8.7B | $1.3B | ||
| Q3 25 | $9.6B | $1.2B | ||
| Q2 25 | $7.4B | $1.3B | ||
| Q1 25 | $6.2B | $1.2B | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $7.5B | $1.0B | ||
| Q2 24 | $5.9B | $739.9M | ||
| Q1 24 | $5.0B | — |
总资产AMGNARDT
| Q4 25 | $90.6B | $5.3B | ||
| Q3 25 | $90.1B | $5.2B | ||
| Q2 25 | $87.9B | $5.0B | ||
| Q1 25 | $89.4B | $4.9B | ||
| Q4 24 | $91.8B | — | ||
| Q3 24 | $90.9B | $4.8B | ||
| Q2 24 | $90.9B | $4.6B | ||
| Q1 24 | $93.0B | — |
负债/权益比AMGNARDT
| Q4 25 | 6.31× | 0.84× | ||
| Q3 25 | 5.67× | 0.88× | ||
| Q2 25 | 7.57× | 0.87× | ||
| Q1 25 | 9.24× | 0.93× | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | 1.08× | ||
| Q2 24 | 10.57× | 1.46× | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $223.4M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 6.5% | — |
| 现金转化率经营现金流/净利润 | 1.20× | 4.97× |
| 过去12个月自由现金流最近4个季度 | $8.1B | — |
8季度趋势，按日历期对齐
经营现金流AMGNARDT
| Q4 25 | $1.6B | $223.4M | ||
| Q3 25 | $4.7B | $154.4M | ||
| Q2 25 | $2.3B | $117.5M | ||
| Q1 25 | $1.4B | $-24.8M | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $3.6B | $89.7M | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $689.0M | — |
自由现金流AMGNARDT
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $980.0M | — | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $459.0M | — |
自由现金流率AMGNARDT
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 48.4% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 26.5% | — | ||
| Q1 24 | 6.2% | — |
资本支出强度AMGNARDT
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.1% | — |
现金转化率AMGNARDT
| Q4 25 | 1.20× | 4.97× | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | 1.61× | ||
| Q1 25 | 0.80× | -0.60× | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | 3.41× | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
ARDT
暂无分部数据
